Aquaporin A/S

AQP

DK0061555109

Water Utilities

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:32 2024-04-26 am EDT			5-day change	1st Jan Change
14.35 ^DKK	-2.05%		-4.01%	-68.80%

Apr. 05	Transcript : Aquaporin A/S, 2023 Earnings Call, Apr 05, 2024
Apr. 05	Aquaporin A/S Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Aquaporin A/S Maintains Earnings Guidance for the Full Year 2023

November 16, 2023 at 01:30 am EST

Aquaporin A/S maintained earnings guidance for the full year 2023. The company maintains the financial outlook for the full year 2023, revenue expected to be in the range of DKK 50 million - DKK 70 million, EBIT (before special items) a loss of DKK 105 million - DKK 95 million.

Latest news about Aquaporin A/S

Transcript : Aquaporin A/S, 2023 Earnings Call, Apr 05, 2024	Apr. 05
Aquaporin A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 05	CI
Aquaporin A/S Provides Earnings Guidance for the Year 2024	Apr. 05	CI
London Stocks Retreat Ahead of Final UK GDP Data for Q4 2023	Mar. 25	MT
AstraZeneca Says Ultomiris Gets US FDA Approval to Treat Neuromyelitis Optica Spectrum Disorder	Mar. 25	MT
AstraZeneca Bags US FDA Clearance for Rare Autoimmune Disease Treatment Ultomiris	Mar. 25	MT
AstraZeneca Receives US Approval for Neuromyelitis Optica Spectrum Disorder Treatment	Mar. 25	MT
Aquaporin Announces Changes in Executive Management Team	Feb. 02	CI
Aquaporin A/S Provides Earnings Guidance for the Financial Year 2024	Jan. 29	CI
Aquaporin A/S(CPSE:AQP) added to OMX Nordic Small Cap Index	Jan. 04	CI
Aquaporin A/S Maintains Earnings Guidance for the Full Year 2023	Nov. 16	CI
AstraZeneca's Soliris Approved in China for Treatment of Neuromyelitis Optica Spectrum Disorder	23-10-18	MT
AstraZeneca drug Solaris approved in China as NMOSD treatment	23-10-18	AN
AstraZeneca's Rare Inflammatory Disease Drug for Adults Wins First-in-Class Nod in China	23-10-18	MT
AstraZeneca working with FDA on Ultomiris risk evaluation changes	23-09-06	AN
Transcript : Aquaporin A/S, H1 2023 Earnings Call, Aug 25, 2023	23-08-25
Aquaporin A/S Reaffirms Earnings Guidance for the Year 2023	23-08-25	CI
Aquaporin A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
AstraZeneca's Ultomiris wins another approval in Japan	23-05-26	AN
AstraZeneca Wins First-in-Class Nod for Rare Inflammatory Disease Drug Ultomiris in Japan	23-05-26	MT
Aquaporin A/S Provides Earnings Guidance of the Full Year 2023	23-05-24	CI
AstraZeneca's Rare Inflammatory Disease Drug Wins First-in-Class EU Approval	23-05-10	MT
AstraZeneca's ultomiris recommended for EU approval	23-04-03	AN
AstraZeneca's Ultomiris Recommended for Marketing Authorization in EU	23-04-03	DJ
Correction: AstraZeneca's Rare Inflammatory Disease Drug Wins EU Health Agency's Positive Recommendation	23-04-03	MT

Chart Aquaporin A/S

Duration

Period

More charts

Company Profile

Aquaporin A/S is a Denmark-based water tech company delivering technology built on natureâs own water filtration. Aquaporin revolutionizes water purification by merging biotechnological techniques and classical engineering. The Companyâs aim is to commercialize biomimetic water membranes for households and industrial use in a variety of markets and applications. Aquaporin deploys direct sales, sales through distributors and commercial partnerships. Aquaporin operates through three segments; Drinking Water, Industrial Water, and Food & Beverage. The Companyâs products include: Forward osmosis membranes, Drinking water membranes, ZERO - water purifier, ONE - water purifier, Brackish water RO membranes and Aquaporin Inside technology.

Sector

Water Utilities

More about the company

Income Statement Evolution

More financial data

Ratings for Aquaporin A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Water Supply & Irrigation Systems

	1st Jan change	Capi.
AQUAPORIN A/S	-68.80%	22.49M
AMERICAN WATER WORKS COMPANY, INC.	-8.49%	23.53B
GUANGDONG INVESTMENT LIMITED	-32.75%	3.19B
BEIJING ENTERPRISES WATER GROUP LIMITED	+13.79%	2.54B
COMPANHIA CATARINENSE DE ÁGUAS E SANEAMENTO - CASAN	-.--%	2.12B
SJW GROUP	-18.13%	1.72B
COMPANHIA DE SANEAMENTO DE MINAS GERAIS	+5.32%	1.6B
COMPANHIA DE SANEAMENTO DO PARANÁ - SANEPAR	-10.87%	1.52B
MANILA WATER COMPANY, INC.	+30.91%	1.24B
GUANGDONG SHUNKONG DEVELOPMENT CO.,LTD.	-11.02%	1.15B

Water Supply & Irrigation Systems

Aquaporin A/S

Equities

AQP

DK0061555109

Water Utilities

Aquaporin A/S Maintains Earnings Guidance for the Full Year 2023

Latest news about Aquaporin A/S

Chart Aquaporin A/S

Company Profile

Income Statement Evolution

Ratings for Aquaporin A/S

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Water Supply & Irrigation Systems